NewsRoom Articles - Page 22 of 228

MondayJul 07, 2025 11:50 am

Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025

The FDA offered supportive feedback on Clene’s proposed statistical analysis plan during a recent Type C meeting. The neurofilament biomarker analysis results could support an accelerated approval submission for CNM-Au8 later in 2025. Clene has two additional FDA meetings scheduled in Q3 2025 to discuss ALS survival data and its MS program. Nearly 200 ALS patients are participating in the NIH-sponsored Expanded Access Program for CNM-Au8. The analysis aims to validate the neuroprotective effects shown in previous HEALEY Platform Trial results. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

MondayJul 07, 2025 9:05 am

20 States File Lawsuit Against Trump Administration for Releasing Medicaid Data to DHS

Rob Bonta, the Attorney General of California, revealed on Tuesday that 20 states have filed a lawsuit challenging the federal government’s release of private Medicaid data to deportation personnel in June. The shared data affects millions of people enrolled in Medicaid. Advisers to the HHS Secretary ordered CMS officials to release private data, including names, immigration status, social security numbers, addresses, as well as claims data by those enrollees in several jurisdictions, such as Washington State, Illinois, Washington, D.C., and California to the Department of Homeland Security (DHS). The states included in the data sharing request were selected because those…

ThursdayJul 03, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis

Nutriband and Kindeva have completed commercial-scale manufacturing for AVERSA(TM) Fentanyl, a major milestone in the path to FDA approval Updated analyst report raises NTRB’s price target to $15.00 and reiterates an Outperform rating, citing favorable trial pathway and strong execution Aversa abuse-deterrent tech is protected by international patents and may address a global unmet need in safe pain management NTRB boosting their profile and credibility with its recent membership to the Russel Indexes The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe…

ThursdayJul 03, 2025 10:00 am

Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy

While studying why non-human primates aren’t as likely to suffer from certain cancers when compared to humans, UC Davis scientists discovered a genetic mutation that could explain this anomaly. Their findings were published in the Nature Communications journal. This discovery could open the door to the development of more powerful treatments for cancer. The researchers focused on Fas Ligand, an immune protein that helps in attacking tumor cells. This protein is present in both human and non-human primates like chimpanzees. The scientists discovered that in humans, a small mutation makes FasL to be easily deactivated by a tumor-linked enzyme called…

WednesdayJul 02, 2025 9:45 am

Adageis: An AI-Powered Advocate for Healthcare Providers

Adageis, a company offering a powerful and patented AI-centric software solution, remains committed to streamlining the healthcare sector, making it easier for providers to meet their financial goals It works with over 90 Electronic Health Record platforms, an unrivalled level of access that gives its users actionable insights at the point of care The company covers over 260,000 patient lives, and looks to double that to 580,000, achieving its $100,000 monthly recurring revenue target Adageis, a company offering powerful and patented AI-based software, provides flexible healthcare and related software solutions for providers and healthcare systems. The company remains committed to…

WednesdayJul 02, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar

A focus during the webinar was the investigator-initiated study currently being conducted at the University of Pennsylvania under the leadership of Dr. Ellen Kim. Interim results show that among the first eight patients who completed 18 weeks of treatment, 75% demonstrated a greater than 50% reduction in disease severity. Soligenix anticipates top-line results from the phase 3 trial in the second half of 2026. In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development (https://ibn.fm/dz7eO). The event offered an in-depth look at…

TuesdayJul 01, 2025 10:00 am

Research Finds That Pesticides Disrupt Inflammation-Linked Bacteria

Existing scientific information shows that pesticides are toxic to the microorganisms in the gut, and a new preclinical study has mapped the specific impacts that compounds in pesticides have on microbes in the human digestive system. One surprising finding emerged regarding how these pesticide compounds affect the inflammatory system in the body. The Ohio State University team of researchers conducted an analysis aimed at establishing the specific ways in which different active ingredients in pesticides impact the ways in which bacteria in the gut grow and how the affected bacteria alter the ways in which nutrients are processed in the…

FridayJun 27, 2025 10:00 am

Research Links Key Proteins to the Growth of Brain Tumors

University of Plymouth researchers in the UK have identified the proteins that underlie the growth and development of common brain tumors. Their findings could, in the long run, trigger the development of new treatments which are less invasive. Through investigations undertaken at labs at the Plymouth Science Park, PhD students, together with other scientists studied the molecular subtypes of tumors called meningiomas. They found that ANXA3, a type of protein, was a key driver behind the growth of some meningioma cells. By inhibiting the functioning of these proteins, the team was able to slow down, and in some instances, altogether…

FridayJun 27, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health priorities. NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application (“ANDA”) with a priority review request. NRx has submitted full CMC data and draft labeling for NRX-100, meeting key Commissioner’s National Priority Voucher pre-qualification criteria. The company’s U.S.-based manufacturing aims to reduce foreign supply chain dependence and address diversion concerns. A patent on the preservative-free process and a citizen petition to withdraw preserved ketamine could bolster NRx’s market position. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and…

ThursdayJun 26, 2025 10:00 am

Why Public Interest in Mitochondrial Function Testing is Growing

Today, more ordinary people are taking an interest in tracking their mitochondrial health in order to take concrete steps to improve their overall wellness and boost longevity. Previously, such interest was a mainstay among elite athletes, scientists and biohacking enthusiasts. Why are more people choosing to have their mitochondrial health tested? For starters, mitochondria are powerhouses inside body cells. These organelles play several vital roles, such as generating energy for cellular use, participating in the immune system’s response to pathogens, contributing to cell signaling, and playing a role in programmed cell death (aka apoptosis). Mitochondrial health is therefore essential to…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025

20 States File Lawsuit Against Trump Administration for Releasing Medicaid Data to DHS

Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis

Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy

Adageis: An AI-Powered Advocate for Healthcare Providers

Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar

Research Finds That Pesticides Disrupt Inflammation-Linked Bacteria

Research Links Key Proteins to the Growth of Brain Tumors

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

Why Public Interest in Mitochondrial Function Testing is Growing

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search